Pharma Focus Europe

Catalent Invests US $175 million in a New Manufacturing Facility in Winchester

Introduction:

Catalent has invested $175 million to develop its flagship U.S. manufacturing plant for large-scale oral dose form in Winchester, Kentucky.

Features:

The project, which is planned to open in January 2024, will increase the production footprint of the site by 107,07,000 square feet.

This expansion will boost the site's highly potent material handling capabilities and containment vault, as well as give more laboratory space and enhance capacity for existing turnkey activities.

Additionally, the capacity for dual fill encapsulation and pan coating, as well as a variety of packaging solutions and analytical services, will be expanded.

When fully operational, the expansion will provide up to 277 new positions, bringing the total number of employees to around 650.

Catalent's investment comes after a 2015 announcement to extend the site's area to 190,000 square feet and a $40 million investment in 2019 that included upgraded equipment for stick pack dose manufacture, integrated packaging lines, and increased roller compaction and fluid bed capacity.

Specifications:

NameCatalent
TypeExpansion
Year2024
magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva